Oncology (all articles)
Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model.
24 Jun, 2022 | 11:07h | UTC
Single-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
24 Jun, 2022 | 10:49h | UTCEZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma.
24 Jun, 2022 | 10:46h | UTCLongitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
News Release: Non-invasive liquid biopsy tracks cancer treatment success in real time – University of Wisconsin–Madison
Commentary: Longitudinal Liquid Biopsy for Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – The ASCO Post
Commentary on Twitter
💡 Longitudinal analysis of circulating tumor cells from metastatic #RenalCellCarcinoma provides insight into changes in both tumor burden & #MolecularProfile of tumor cells in response to treatment. #JCO #kcsm @joshlangmd https://t.co/fPU8PepHJR pic.twitter.com/cKPvXiPB0W
— Journal of Clinical Oncology (@JCO_ASCO) June 10, 2022
Consensus report on anatomy, pathophysiology and clinical significance of the gastro-esophageal junction.
23 Jun, 2022 | 10:26h | UTC
International consensus statements on pre-invasive vulvar lesions.
23 Jun, 2022 | 10:21h | UTCNews Release: New Guidelines Address Treatment of Pre-Invasive Lesions of the Vulva – Wolters Kluwer Health: Lippincott
M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.
23 Jun, 2022 | 10:10h | UTC
Phase II RCT: FLOT vs. FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma.
23 Jun, 2022 | 09:58h | UTCFLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group – Journal of Clinical Oncology (link to abstract – $ for full-text)
Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.
23 Jun, 2022 | 09:57h | UTC
Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
23 Jun, 2022 | 09:54h | UTC
ASCO Guideline: Management of metastatic clear cell renal cell carcinoma.
22 Jun, 2022 | 11:30h | UTC
Cohort Study: Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment.
22 Jun, 2022 | 10:51h | UTCCommentaries:
Polypharmacy can lead to harmful drug interactions, especially among cancer patients – News Medical
Analysis Underscores Risks of Polypharmacy in Elderly Patients With Cancer – AJMC
Commentary on Twitter
Our new article in @OncJournal : In a large cohort of older adults with advanced cancer, polypharmacy &PIM are very common. Nonprescription meds are frequently PIMs &involved in potential harmful drug interactions @WilmotCancer @rochgerionc @myCARGhttps://t.co/bA7W4kyybm pic.twitter.com/zFI3EgS320
— Mostafa R Mohamed (@m_refaat84) April 2, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license
Phase II RCT: Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer.
22 Jun, 2022 | 10:49h | UTCSwitch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Long-term follow-up of a RCT: Nivolumab plus cabozantinib vs. sunitinib in first-line treatment for advanced renal cell carcinoma.
22 Jun, 2022 | 10:48h | UTCNivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine
Commentary from the author on Twitter (thread – click for more)
1/ CheckMate-9ER extended f/u (media f/u=32.9mo) results out in @TheLancetOncol: preplanned final OS analysis, updated PFS, OR & safety of Cabo/Nivo vs. Sun in 1L RCC. Also includes prespecified & post-hoc subgroup analyses. https://t.co/OJduO7Q2ar@OncoAlert @DanaFarber_GU pic.twitter.com/0EQN5gWu5I
— Toni Choueiri, MD (@DrChoueiri) June 8, 2022
RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.
21 Jun, 2022 | 11:11h | UTCOriginal Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Randomized trial showed that treating anal high-grade squamous intraepithelial lesions (HSILs) led to a 57% reduction in progression to anal cancer as compared with active surveillance. https://t.co/iulcskP61C pic.twitter.com/Q6Oqty3hgW
— NEJM (@NEJM) June 15, 2022
Consensus definition and management recommendations: intermediate-risk non–muscle-invasive bladder cancer.
21 Jun, 2022 | 10:52h | UTCIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (if the link is paywalled, try this one)
Commentary from the author on Twitter
Intermediate-risk NMIBC: Updated Consensus Definition & Management Recs from IBCG (International Bladder Cancer Group)
Full text: https://t.co/QaqGqRN3AE @drtanws @garysteinbergmd @DrShariat @UrogerliMD @MRoupret @spsutkaMD @joanfundi @MarekBabjuk @SWilliams_MD #bladdercancer pic.twitter.com/XQ1sdhqXPZ— Ashish M. Kamat, MD, MBBS (@UroDocAsh) June 17, 2022
RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.
21 Jun, 2022 | 10:48h | UTCLisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Onconephrology: Update in anticancer drug-related nephrotoxicity.
21 Jun, 2022 | 10:47h | UTCOnconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron
Related:
Commentary from the author on Twitter
Just published! Our review about anticancer drugs related kidney injury with @PepaSolerR and @julianadraibe @SENefrologia @onconephsociety @onconefrologia @senjoven @ERAkidney @womeninnephro https://t.co/jFStKwym5z @KargerPublisher pic.twitter.com/zvbl7wxAbD
— Clara García Carro (@ClaraGCarro) June 20, 2022
RCT: Active surveillance plus Enzalutamide monotherapy vs. active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer.
21 Jun, 2022 | 10:33h | UTCInvited Commentary: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (free for a limited period)
Video criticizing the article: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad
Commentaries on Twitter
55% fatigue and 36% gynecomastia. In AS patients.
Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65
— Chris Barbieri (@Chris_Barbieri1) June 17, 2022
The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) June 16, 2022
Clinical and immunologic analyses of a phase II trial: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer.
21 Jun, 2022 | 10:26h | UTCNews Release: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania
Commentary on Twitter
At #ASCO22 Symposium on targeted therapy in GI cancer?
Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici
Published today 👉 https://t.co/8aUXuvDHIC
— Nature Medicine (@NatureMedicine) June 3, 2022
NCCN Updated Guideline: Breast cancer.
20 Jun, 2022 | 01:24h | UTC
Single-arm phase 2b study: MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer.
20 Jun, 2022 | 00:56h | UTCMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Radiomic assessment of esophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT.
20 Jun, 2022 | 00:53h | UTC
Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.
20 Jun, 2022 | 00:51h | UTC
Cohort Study: Association of screening with digital breast tomosynthesis vs. digital mammography with risk of interval invasive and advanced breast cancer.
17 Jun, 2022 | 11:09h | UTCAssociation of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer – JAMA (free for a limited period)
Editorial: Digital Breast Tomosynthesis and Detection of Interval Invasive and Advanced Breast Cancers – JAMA (free for a limited period)
News Release: 3-D Mammography Technique Benefits Some Women, Not All – University of California San Francisco
Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer in China: a national database study of 5055 patients.
15 Jun, 2022 | 10:49h | UTC